Gilead Sciences (GILD) 107.99 $GILD
Stocks Rally Ahead of Next Week's Fed Meeting, Apple Earnings
at The Street - Fri Oct 23, 3:16PM CDT
The question now is whether the market's feel-good mood will carry over into the coming week, especially with the Federal Reverse's latest policy meeting mid-week.
XOM: 82.98 (+0.09), PYPL: 34.99 (+0.20), INTC: 34.90 (+0.50), YHOO: 33.17 (+1.50), P: 12.39 (-6.80), XLK: 43.83 (+1.19), ABBV: 50.34 (+2.07), GOOGL: 719.33 (+38.19), TMUS: 41.27 (+0.83), TWTR: 30.28 (+1.13), MSFT: 52.87 (+4.84), AAPL: 119.08 (+3.58), GPRO: 29.15 (+0.43), PSX: 83.35 (+0.74), AMZN: 599.03 (+35.12), EXC: 29.86 (-1.15), FB: 102.19 (+2.52), PFE: 34.05 (+0.72), STX: 41.15 (+1.91), VFC: 63.75 (-9.46), BIDU: 157.60 (+4.10), GILD: 107.99 (+0.39), PG: 77.03 (+2.18), CVX: 91.24 (-0.38), CMCSA: 61.98 (+0.28), BABA: 75.62 (+4.63)
What's in Store for Gilead (GILD) this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Fri Oct 23, 3:00PM CDT
Gilead Sciences Inc. (GILD) is scheduled to report third-quarter 2015 results on Oct 27.
GILD: 107.99 (+0.39), AMAG: 37.85 (+4.24), ANIK: 34.87 (+1.25), KERX: 4.47 (-0.20)
Jim Cramer Favors Eli Lilly, Calls P&G a Catch-Up Trade
at The Street - Fri Oct 23, 2:13PM CDT
TheStreet's Jim Cramer shares his thoughts on Procter & Gamble, FireEye, Twitter, Eli Lilly and more, when answering viewers questions.
JNJ: 100.31 (+0.78), FEYE: 27.23 (-2.14), GILD: 107.99 (+0.39), LLY: 78.31 (+1.33), PG: 77.03 (+2.18), TWTR: 30.28 (+1.13), AAPL: 119.08 (+3.58)
Business events scheduled for the coming week
By The Associated Press - AP - Fri Oct 23, 12:43PM CDT
All times are Eastern.
RAI: 48.89 (+0.01), F: 15.67 (+0.09), QSR.TO: 49.17 (+0.57), ANTX: 47.28 (+0.16), PFE: 34.05 (+0.72), XOM: 82.98 (+0.09), AMGN: 155.75 (+3.44), CMCSK: 62.35 (+0.28), MO: 61.05 (-0.35), AET: 105.89 (+2.53), SBUX: 62.61 (+1.12), ANTM: 140.95 (+1.54), QSR: 37.33 (+0.33), GT: 32.97 (+0.40), WBA: 89.96 (+1.33), GILD: 107.99 (+0.39), MRK: 52.88 (+0.87), CVS: 103.95 (-0.34), TWTR: 30.28 (+1.13), CMCSA: 61.98 (+0.28), AAPL: 119.08 (+3.58), BABA: 75.62 (+4.63)
Gilead Wins in Hepatitis C Market
at The Street - Fri Oct 23, 11:00AM CDT
ABBV gets FDA warning on Viekira Pak drug, GILD reaps the reward.
ESRX: 85.11 (+2.42), GILD: 107.99 (+0.39), MRK: 52.88 (+0.87), ABBV: 50.34 (+2.07)
AbbVie Slumps, FDA Issues Warning Related to 2 HCV Drugs
Zacks Equity Research - Zacks Investment Research - Fri Oct 23, 10:56AM CDT
AbbVie's (ABBV) shares plunged 10.3% after the FDA came up with a warning related to two HCV drugs, Viekira Pak and Technivie; the company was compelled to revise labels.
GILD: 107.99 (+0.39), MRK: 52.88 (+0.87), AZN: 31.36 (+0.29), ABBV: 50.34 (+2.07)
Gilead Sciences (GILD) Jumps: Stock Adds 5.8% in Session
Zacks Equity Research - Zacks Investment Research - Fri Oct 23, 7:15AM CDT
Gilead Sciences Inc. (GILD) shares rose almost 6% in the last trading session.
GILD: 107.99 (+0.39)
FDA warns of deadly liver damage with AbbVie hepatitis drugs
By MATTHEW PERRONE - AP - Thu Oct 22, 5:02PM CDT
WASHINGTON (AP) — Federal health officials are warning doctors and patients that two hepatitis C drugs from AbbVie can cause life-threatening liver injury in patients with advanced forms of the disease.
JNJ: 100.31 (+0.78), GILD: 107.99 (+0.39), MRK: 52.88 (+0.87)
Shares of AbbVie Inc Plummeted Today. Here's Why.
Brian Feroldi, The Motley Fool - Motley Fool - Thu Oct 22, 3:49PM CDT
What: Shares of pharma giant AbbVie plunged by more than 14% today in late afternoon trading after the company received a warning letter from the FDA related to its two Hepatitis C medications. So what: The FDA issued a warning related to the...
GILD: 107.99 (+0.39), ABBV: 50.34 (+2.07)
Achillion, J&J's HCV Combo Drug Phase IIa Study Started
Zacks Equity Research - Zacks Investment Research - Thu Oct 22, 3:45PM CDT
Achillion Pharmaceuticals (ACHN) announced the initiation of a phase IIa study evaluating the combination of AL-335, odalasvir and Olysio for genotype 1 chronic HCV.
JNJ: 100.31 (+0.78), GILD: 107.99 (+0.39), ACHN: 8.10 (+0.11), ABBV: 50.34 (+2.07)
After Yesterday's Rally of 5.77% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Oct 22, 3:43PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $100.40 to a high of $109.42. Yesterday, the shares gained 5.8%, which took the trading range above the 3-day high of $103.95 on volume of 24.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
GILD: 107.99 (+0.39)
Watch for Gilead Sciences to Potentially Pullback After Gaining 5.77% Yesterday
Comtex SmarTrend(R) - Thu Oct 22, 3:42PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $100.40 to a high of $109.42. Yesterday, the shares gained 5.8%, which took the trading range above the 3-day high of $103.95 on volume of 24.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
GILD: 107.99 (+0.39)
AbbVie Hepatitis C Drugs Hit By FDA Warning
at Investor's Business Daily - Thu Oct 22, 3:34PM CDT
The FDA said Thursday that it's requiring that a warning of liver damage be put on the labels of AbbVie's (ABBV) hepatitis C treatments Viekira Pak and Technivie, sending AbbVie shares plunging to an 18-month low and those of Gilead Sciences (GILD)...
ESRX: 85.11 (+2.42), GILD: 107.99 (+0.39), MRK: 52.88 (+0.87), ABBV: 50.34 (+2.07), ENTA: 24.01 (+0.11)
Hurricane Hillary Shifts Left, Slamming More Stocks
at Investor's Business Daily - Thu Oct 22, 2:52PM CDT
Hillary Clinton has demonstrated a knack for striking fear in the hearts of investors -- first in pharmaceuticals, then in health insurance and now in cable TV. For example, the beginning of Valeant's (VRX) nearly 60% plunge in the last month can be...
BIIB: 276.99 (+0.16), VRX: 116.16 (+6.29), BMRN: 104.14 (+2.54), UNH: 115.92 (+2.11), CHTR: 183.00 (+4.62), AET: 105.89 (+2.53), HUM: 168.20 (+3.09), CI: 132.54 (+3.05), ANTM: 140.95 (+1.54), GILD: 107.99 (+0.39), TWC: 185.19 (+2.29), CMCSA: 61.98 (+0.28), REGN: 536.70 (+11.59)
No Easy Cure for What Ails Biotech Stocks
at The Street - Thu Oct 22, 10:30AM CDT
Meanwhile, make incremental moves until the onslaught in the space is over.
BIIB: 276.99 (+0.16), VRX: 116.16 (+6.29), GILD: 107.99 (+0.39), MYL: 40.96 (+1.80), AMGN: 155.75 (+3.44)
Polycythemia Vera Pipeline Review, H2 2015 - 10 Companies & 12 Drug Profiles
M2 - Thu Oct 22, 8:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wswf9z/polycythemia_vera) has announced the addition of the "Polycythemia Vera - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Polycythemia Vera, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polycythemia Vera and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Galena Biopharma, Inc. - Gilead Sciences, Inc. - Incyte Corporation - Italfarmaco S.p.A. - Karus Therapeutics Limited - miRagen Therapeutics, Inc. - Novartis AG - Onconova Therapeutics, Inc. - PharmaEssentia Corporation Drug Profiles - anagrelide hydrochloride CR - dasatinib - erismodegib - givinostat - idelalisib - KA-1463 - M-012 - MGN-4893 - momelotinib dihydrochloride - rigosertib sodium - ropeginterferon ALFA-2B - ruxolitinib phosphate For more information visit http://www.researchandmarkets.com/research/ws...hemia_vera
GILD: 107.99 (+0.39), INCY: 110.02 (+1.00), ONTX: 1.49 (+0.03), GALE: 1.67 (+0.05), BMY: 65.16 (+1.98), NVS: 92.98 (+0.55)
Gilead Announces Phase 3 Results for Genvoya(R) (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide), an Investigational Once-Daily Single Tablet Regimen for HIV
Business Wire - Thu Oct 22, 6:33AM CDT
Gilead Sciences, Inc. (NASDAQ:GILD) today announced 96-week results from two Phase 3 studies (Studies 104 and 111) evaluating its investigational once-daily single tablet regimen (STR), Genvoya(R) (elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg or E/C/F/TAF), for the treatment of HIV-1 infection in treatment-naive adults. Genvoya was found to be statistically non-inferior to Stribild(R) (elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg or E/C/F/TDF), based on percentages of patients with HIV-1 RNA levels less than 50 copies/mL. Patients receiving Genvoya also had improved renal and bone laboratory parameters compared to those treated with Stribild. The data were presented at the 15th European AIDS Conference (EACS) in Barcelona (session: BD 01).
GILD: 107.99 (+0.39)
Battle Royale: Gilead Sciences Inc vs Celgene Corporation
Brian Feroldi, The Motley Fool - Motley Fool - Wed Oct 21, 2:09PM CDT
Photo by Mattza / Flickr creative Commons It's been a rough couple of months to be a biotech focused investor. Since peaking in price over the summer, biotech stocks on the whole have basically been in free-fall. The iShares Nasdaq Biotechnology...
GILD: 107.99 (+0.39), CELG: 120.08 (+2.82)
Stocks Turn Lower as Valeant Dents Biotech Sector
at The Street - Wed Oct 21, 9:41AM CDT
Stocks turn lower by mid-morning Wednesday as plummeting Valeant Pharmaceuticals shares pull the biotech sector to the downside.
BIIB: 276.99 (+0.16), TSLA: 209.09 (-2.63), VRX: 116.16 (+6.29), KMB: 121.24 (+0.44), IBB: 316.28 (+10.17), SBUX: 62.61 (+1.12), YHOO: 33.17 (+1.50), CMG: 649.72 (-0.90), ABBV: 50.34 (+2.07), GOOGL: 719.33 (+38.19), AAPL: 119.08 (+3.58), KO: 42.79 (-0.45), AMZN: 599.03 (+35.12), MU: 17.24 (+0.52), PFE: 34.05 (+0.72), FCAU: 15.37 (+0.13), BA: 146.70 (+0.39), WDC: 69.34 (-0.62), CELG: 120.08 (+2.82), GILD: 107.99 (+0.39), LRCX: 74.57 (+1.96), GM: 35.95 (+0.53), MCD: 112.59 (+1.72), KLAC: 65.35 (+0.45), RACE: 56.38 (-0.37), SNDK: 78.37 (+1.28)
Stock Market News for October 21, 2015
Zacks Equity Research - Zacks Investment Research - Wed Oct 21, 9:10AM CDT
Benchmarks ended in the red on Tuesday, dragged down by declines in biotech and healthcare stocks
BIIB: 276.99 (+0.16), HOG: 48.20 (+0.09), IBM: 144.68 (+0.59), GILD: 107.99 (+0.39), UTX: 100.62 (+0.83), PFE: 34.05 (+0.72), MRK: 52.88 (+0.87), AMGN: 155.75 (+3.44), VZ: 46.16 (+0.27), REGN: 536.70 (+11.59), TRV: 112.28 (-0.04), CELG: 120.08 (+2.82)
Stocks Rally Ahead of Next Week's Fed Meeting, Apple Earnings
at The Street - Fri Oct 23, 3:16PM CDT
The question now is whether the market's feel-good mood will carry over into the coming week, especially with the Federal Reverse's latest policy meeting mid-week.
XOM: 82.98 (+0.09), PYPL: 34.99 (+0.20), INTC: 34.90 (+0.50), YHOO: 33.17 (+1.50), P: 12.39 (-6.80), XLK: 43.83 (+1.19), ABBV: 50.34 (+2.07), GOOGL: 719.33 (+38.19), TMUS: 41.27 (+0.83), TWTR: 30.28 (+1.13), MSFT: 52.87 (+4.84), AAPL: 119.08 (+3.58), GPRO: 29.15 (+0.43), PSX: 83.35 (+0.74), AMZN: 599.03 (+35.12), EXC: 29.86 (-1.15), FB: 102.19 (+2.52), PFE: 34.05 (+0.72), STX: 41.15 (+1.91), VFC: 63.75 (-9.46), BIDU: 157.60 (+4.10), GILD: 107.99 (+0.39), PG: 77.03 (+2.18), CVX: 91.24 (-0.38), CMCSA: 61.98 (+0.28), BABA: 75.62 (+4.63)
What's in Store for Gilead (GILD) this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Fri Oct 23, 3:00PM CDT
Gilead Sciences Inc. (GILD) is scheduled to report third-quarter 2015 results on Oct 27.
GILD: 107.99 (+0.39), AMAG: 37.85 (+4.24), ANIK: 34.87 (+1.25), KERX: 4.47 (-0.20)
Jim Cramer Favors Eli Lilly, Calls P&G a Catch-Up Trade
at The Street - Fri Oct 23, 2:13PM CDT
TheStreet's Jim Cramer shares his thoughts on Procter & Gamble, FireEye, Twitter, Eli Lilly and more, when answering viewers questions.
JNJ: 100.31 (+0.78), FEYE: 27.23 (-2.14), GILD: 107.99 (+0.39), LLY: 78.31 (+1.33), PG: 77.03 (+2.18), TWTR: 30.28 (+1.13), AAPL: 119.08 (+3.58)
Business events scheduled for the coming week
By The Associated Press - AP - Fri Oct 23, 12:43PM CDT
All times are Eastern.
RAI: 48.89 (+0.01), F: 15.67 (+0.09), QSR.TO: 49.17 (+0.57), ANTX: 47.28 (+0.16), PFE: 34.05 (+0.72), XOM: 82.98 (+0.09), AMGN: 155.75 (+3.44), CMCSK: 62.35 (+0.28), MO: 61.05 (-0.35), AET: 105.89 (+2.53), SBUX: 62.61 (+1.12), ANTM: 140.95 (+1.54), QSR: 37.33 (+0.33), GT: 32.97 (+0.40), WBA: 89.96 (+1.33), GILD: 107.99 (+0.39), MRK: 52.88 (+0.87), CVS: 103.95 (-0.34), TWTR: 30.28 (+1.13), CMCSA: 61.98 (+0.28), AAPL: 119.08 (+3.58), BABA: 75.62 (+4.63)
Gilead Wins in Hepatitis C Market
at The Street - Fri Oct 23, 11:00AM CDT
ABBV gets FDA warning on Viekira Pak drug, GILD reaps the reward.
ESRX: 85.11 (+2.42), GILD: 107.99 (+0.39), MRK: 52.88 (+0.87), ABBV: 50.34 (+2.07)
AbbVie Slumps, FDA Issues Warning Related to 2 HCV Drugs
Zacks Equity Research - Zacks Investment Research - Fri Oct 23, 10:56AM CDT
AbbVie's (ABBV) shares plunged 10.3% after the FDA came up with a warning related to two HCV drugs, Viekira Pak and Technivie; the company was compelled to revise labels.
GILD: 107.99 (+0.39), MRK: 52.88 (+0.87), AZN: 31.36 (+0.29), ABBV: 50.34 (+2.07)
Gilead Sciences (GILD) Jumps: Stock Adds 5.8% in Session
Zacks Equity Research - Zacks Investment Research - Fri Oct 23, 7:15AM CDT
Gilead Sciences Inc. (GILD) shares rose almost 6% in the last trading session.
GILD: 107.99 (+0.39)
FDA warns of deadly liver damage with AbbVie hepatitis drugs
By MATTHEW PERRONE - AP - Thu Oct 22, 5:02PM CDT
WASHINGTON (AP) — Federal health officials are warning doctors and patients that two hepatitis C drugs from AbbVie can cause life-threatening liver injury in patients with advanced forms of the disease.
JNJ: 100.31 (+0.78), GILD: 107.99 (+0.39), MRK: 52.88 (+0.87)
Shares of AbbVie Inc Plummeted Today. Here's Why.
Brian Feroldi, The Motley Fool - Motley Fool - Thu Oct 22, 3:49PM CDT
What: Shares of pharma giant AbbVie plunged by more than 14% today in late afternoon trading after the company received a warning letter from the FDA related to its two Hepatitis C medications. So what: The FDA issued a warning related to the...
GILD: 107.99 (+0.39), ABBV: 50.34 (+2.07)
Achillion, J&J's HCV Combo Drug Phase IIa Study Started
Zacks Equity Research - Zacks Investment Research - Thu Oct 22, 3:45PM CDT
Achillion Pharmaceuticals (ACHN) announced the initiation of a phase IIa study evaluating the combination of AL-335, odalasvir and Olysio for genotype 1 chronic HCV.
JNJ: 100.31 (+0.78), GILD: 107.99 (+0.39), ACHN: 8.10 (+0.11), ABBV: 50.34 (+2.07)
After Yesterday's Rally of 5.77% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Oct 22, 3:43PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $100.40 to a high of $109.42. Yesterday, the shares gained 5.8%, which took the trading range above the 3-day high of $103.95 on volume of 24.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
GILD: 107.99 (+0.39)
Watch for Gilead Sciences to Potentially Pullback After Gaining 5.77% Yesterday
Comtex SmarTrend(R) - Thu Oct 22, 3:42PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $100.40 to a high of $109.42. Yesterday, the shares gained 5.8%, which took the trading range above the 3-day high of $103.95 on volume of 24.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
GILD: 107.99 (+0.39)
AbbVie Hepatitis C Drugs Hit By FDA Warning
at Investor's Business Daily - Thu Oct 22, 3:34PM CDT
The FDA said Thursday that it's requiring that a warning of liver damage be put on the labels of AbbVie's (ABBV) hepatitis C treatments Viekira Pak and Technivie, sending AbbVie shares plunging to an 18-month low and those of Gilead Sciences (GILD)...
ESRX: 85.11 (+2.42), GILD: 107.99 (+0.39), MRK: 52.88 (+0.87), ABBV: 50.34 (+2.07), ENTA: 24.01 (+0.11)
Hurricane Hillary Shifts Left, Slamming More Stocks
at Investor's Business Daily - Thu Oct 22, 2:52PM CDT
Hillary Clinton has demonstrated a knack for striking fear in the hearts of investors -- first in pharmaceuticals, then in health insurance and now in cable TV. For example, the beginning of Valeant's (VRX) nearly 60% plunge in the last month can be...
BIIB: 276.99 (+0.16), VRX: 116.16 (+6.29), BMRN: 104.14 (+2.54), UNH: 115.92 (+2.11), CHTR: 183.00 (+4.62), AET: 105.89 (+2.53), HUM: 168.20 (+3.09), CI: 132.54 (+3.05), ANTM: 140.95 (+1.54), GILD: 107.99 (+0.39), TWC: 185.19 (+2.29), CMCSA: 61.98 (+0.28), REGN: 536.70 (+11.59)
No Easy Cure for What Ails Biotech Stocks
at The Street - Thu Oct 22, 10:30AM CDT
Meanwhile, make incremental moves until the onslaught in the space is over.
BIIB: 276.99 (+0.16), VRX: 116.16 (+6.29), GILD: 107.99 (+0.39), MYL: 40.96 (+1.80), AMGN: 155.75 (+3.44)
Polycythemia Vera Pipeline Review, H2 2015 - 10 Companies & 12 Drug Profiles
M2 - Thu Oct 22, 8:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wswf9z/polycythemia_vera) has announced the addition of the "Polycythemia Vera - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Polycythemia Vera, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polycythemia Vera and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Galena Biopharma, Inc. - Gilead Sciences, Inc. - Incyte Corporation - Italfarmaco S.p.A. - Karus Therapeutics Limited - miRagen Therapeutics, Inc. - Novartis AG - Onconova Therapeutics, Inc. - PharmaEssentia Corporation Drug Profiles - anagrelide hydrochloride CR - dasatinib - erismodegib - givinostat - idelalisib - KA-1463 - M-012 - MGN-4893 - momelotinib dihydrochloride - rigosertib sodium - ropeginterferon ALFA-2B - ruxolitinib phosphate For more information visit http://www.researchandmarkets.com/research/ws...hemia_vera
GILD: 107.99 (+0.39), INCY: 110.02 (+1.00), ONTX: 1.49 (+0.03), GALE: 1.67 (+0.05), BMY: 65.16 (+1.98), NVS: 92.98 (+0.55)
Gilead Announces Phase 3 Results for Genvoya(R) (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide), an Investigational Once-Daily Single Tablet Regimen for HIV
Business Wire - Thu Oct 22, 6:33AM CDT
Gilead Sciences, Inc. (NASDAQ:GILD) today announced 96-week results from two Phase 3 studies (Studies 104 and 111) evaluating its investigational once-daily single tablet regimen (STR), Genvoya(R) (elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg or E/C/F/TAF), for the treatment of HIV-1 infection in treatment-naive adults. Genvoya was found to be statistically non-inferior to Stribild(R) (elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg or E/C/F/TDF), based on percentages of patients with HIV-1 RNA levels less than 50 copies/mL. Patients receiving Genvoya also had improved renal and bone laboratory parameters compared to those treated with Stribild. The data were presented at the 15th European AIDS Conference (EACS) in Barcelona (session: BD 01).
GILD: 107.99 (+0.39)
Battle Royale: Gilead Sciences Inc vs Celgene Corporation
Brian Feroldi, The Motley Fool - Motley Fool - Wed Oct 21, 2:09PM CDT
Photo by Mattza / Flickr creative Commons It's been a rough couple of months to be a biotech focused investor. Since peaking in price over the summer, biotech stocks on the whole have basically been in free-fall. The iShares Nasdaq Biotechnology...
GILD: 107.99 (+0.39), CELG: 120.08 (+2.82)
Stocks Turn Lower as Valeant Dents Biotech Sector
at The Street - Wed Oct 21, 9:41AM CDT
Stocks turn lower by mid-morning Wednesday as plummeting Valeant Pharmaceuticals shares pull the biotech sector to the downside.
BIIB: 276.99 (+0.16), TSLA: 209.09 (-2.63), VRX: 116.16 (+6.29), KMB: 121.24 (+0.44), IBB: 316.28 (+10.17), SBUX: 62.61 (+1.12), YHOO: 33.17 (+1.50), CMG: 649.72 (-0.90), ABBV: 50.34 (+2.07), GOOGL: 719.33 (+38.19), AAPL: 119.08 (+3.58), KO: 42.79 (-0.45), AMZN: 599.03 (+35.12), MU: 17.24 (+0.52), PFE: 34.05 (+0.72), FCAU: 15.37 (+0.13), BA: 146.70 (+0.39), WDC: 69.34 (-0.62), CELG: 120.08 (+2.82), GILD: 107.99 (+0.39), LRCX: 74.57 (+1.96), GM: 35.95 (+0.53), MCD: 112.59 (+1.72), KLAC: 65.35 (+0.45), RACE: 56.38 (-0.37), SNDK: 78.37 (+1.28)
Stock Market News for October 21, 2015
Zacks Equity Research - Zacks Investment Research - Wed Oct 21, 9:10AM CDT
Benchmarks ended in the red on Tuesday, dragged down by declines in biotech and healthcare stocks
BIIB: 276.99 (+0.16), HOG: 48.20 (+0.09), IBM: 144.68 (+0.59), GILD: 107.99 (+0.39), UTX: 100.62 (+0.83), PFE: 34.05 (+0.72), MRK: 52.88 (+0.87), AMGN: 155.75 (+3.44), VZ: 46.16 (+0.27), REGN: 536.70 (+11.59), TRV: 112.28 (-0.04), CELG: 120.08 (+2.82)
